Complete the pivotal bioequivalence trial of Renazorb
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 15 Aug 2022
- Due
- 31 Dec 2022
- Delivered
- 28 Dec 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“keeps us on track to complete the study around yearend”
What we found
Evidence strength A What the grades mean
Unicycive announced completion of the pivotal Renazorb bioequivalence trial and achievement of primary endpoint on December 28, 2022, meeting the year-end 2022 deadline.
-
A Unicycive Announces Second Quarter Financial Results
“Toward that end, we were delighted to initiate our pivotal bioequivalence trial of Renazorb®, which keeps us on track to complete the study around yearend and to file a New Drug Application (NDA) in 2023.” ✓ confirmed on the page
-
A Unicycive Announces Third Quarter Financial Results
“The third quarter of 2022 and recent weeks have been particularly productive as we completed enrollment of our pivotal bioequivalence trial of RENAZORB, with topline results expected by year-end.” ✓ confirmed on the page
-
B Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
“Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the primary endpoint was met in the Company's pivotal bioequivalence (BE) study comparing Renazorb to Fosrenol®.” ✓ confirmed on the page
Checked 3 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Renazorb bioequivalence trial
- Language
- Firm (“will”, “on track to”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Unicycive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-UNCY-002772 · Corrections policy